Insmed Inc
INSM69.690USD
+0.730+1.06%
收盘 04/25, 16:00（美东）报价延迟15分钟
12.50B总市值
亏损市盈率 TTM
关于 Insmed Inc 公司
Insmed Incorporated 是一家全球生物制药公司。该公司正在推进一系列已获批准和中后期研究药物以及药物发现。其先进的项目涉及肺部和炎症疾病，包括一种在美国、欧洲和日本获批的治疗慢性、衰弱性肺病的疗法。该公司的临床前研究项目涵盖广泛的技术和模式，包括基因治疗、人工智能驱动的蛋白质工程、蛋白质制造、RNA 末端连接和合成救援。其首款商业产品 ARIKAYCE（阿米卡星脂质体吸入混悬液）用于治疗鸟分枝杆菌复合体 (MAC) 肺病，作为联合抗菌药物方案的一部分，用于治疗治疗选择有限或没有替代治疗方案的成人患者。其产品线包括临床阶段项目、brensocatib、TPIP 和 INS1201 以及临床前研究项目。
公司简介
公司代码INSM
公司名称Insmed Inc
上市日期Feb 15, 1991
成立日期1999
CEOMr. William H. (Will) Lewis, J.D.
员工数量1271
证券类型Ordinary Share
年结日Feb 15
公司地址700 Us Highway 202/206
城市BRIDGEWATER
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编08807
电话19089779900
网址https://insmed.com/
公司代码INSM
上市日期Feb 15, 1991
成立日期1999
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
-20.28%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
342.46K
-0.50%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
108.71K
-10.80%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
66.00K
-6.37%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
45.10K
-22.59%
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Chief Financial Officer
Chief Financial Officer
25.57K
-14.67%
Dr. Martina Flammer, M.D.
Dr. Martina Flammer, M.D.
Chief Medical Officer
Chief Medical Officer
12.68K
-28.40%
Mr. Leo Lee
Mr. Leo Lee
Independent Director
Independent Director
--
--
Mr. Alfred F. (Al) Altomari
Mr. Alfred F. (Al) Altomari
Independent Director
Independent Director
--
--
Dr. Clarissa Desjardins, Ph.D.
Dr. Clarissa Desjardins, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
-20.28%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
342.46K
-0.50%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
108.71K
-10.80%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
66.00K
-6.37%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
45.10K
-22.59%
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Chief Financial Officer
Chief Financial Officer
25.57K
-14.67%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
暂无数据
地区USD
名称
营收
占比
US
254.80M
70.06%
Japan
87.70M
24.11%
Europe and rest of worldld
21.21M
5.83%
业务
地区
暂无数据
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.00%
BlackRock Institutional Trust Company, N.A.
7.24%
Darwin Global Management Ltd
7.13%
T. Rowe Price Associates, Inc.
6.90%
Capital International Investors
3.91%
Other
64.81%
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.00%
BlackRock Institutional Trust Company, N.A.
7.24%
Darwin Global Management Ltd
7.13%
T. Rowe Price Associates, Inc.
6.90%
Capital International Investors
3.91%
Other
64.81%
股东类型
股东统计
占比
Investment Advisor
47.42%
Investment Advisor/Hedge Fund
38.22%
Hedge Fund
20.45%
Research Firm
2.06%
Sovereign Wealth Fund
1.01%
Individual Investor
0.91%
Pension Fund
0.79%
Venture Capital
0.79%
Bank and Trust
0.45%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
759
205.28M
112.91%
-2.19M
2024Q4
767
205.04M
113.32%
-2.57M
2024Q3
712
200.94M
112.58%
+1.71M
2024Q2
657
186.57M
112.00%
+21.58M
2024Q1
564
156.59M
105.42%
-6.86M
2023Q4
544
155.47M
105.16%
-6.81M
2023Q3
515
153.95M
107.69%
-8.46M
2023Q2
506
152.37M
106.87%
-10.75M
2023Q1
511
151.28M
110.90%
-8.90M
2022Q4
518
148.20M
109.35%
+6.87M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
18.18M
10%
+1.07M
+6.27%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
13.17M
7.24%
+962.07K
+7.88%
Dec 31, 2024
Darwin Global Management Ltd
12.96M
7.13%
+2.46M
+23.47%
Dec 31, 2024
T. Rowe Price Associates, Inc.
12.55M
6.9%
+164.62K
+1.33%
Dec 31, 2024
Capital International Investors
7.12M
3.91%
+593.21K
+9.09%
Dec 31, 2024
Capital Research Global Investors
6.32M
3.47%
+559.29K
+9.72%
Dec 31, 2024
State Street Global Advisors (US)
6.11M
3.36%
-72.08K
-1.17%
Dec 31, 2024
Baker Bros. Advisors LP
5.01M
2.75%
+590.95K
+13.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.67M
2.57%
-1.83M
-28.09%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.09M
2.25%
+273.76K
+7.18%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
BNY Mellon Innovators ETF
4.06%
VanEck Biotech ETF
2.45%
Franklin Genomic Advancements ETF
2.39%
SPDR S&P Biotech ETF
2.31%
Goldman Sachs Hedge Industry VIP ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.83%
Direxion Daily S&P Biotech Bull 3X Shares
1.47%
Invesco Nasdaq Biotechnology ETF
1.39%
ProShares Ultra Nasdaq Biotechnology
1.38%
iShares Biotechnology ETF
1.25%
查看更多
BNY Mellon Innovators ETF
占比4.06%
VanEck Biotech ETF
占比2.45%
Franklin Genomic Advancements ETF
占比2.39%
SPDR S&P Biotech ETF
占比2.31%
Goldman Sachs Hedge Industry VIP ETF
占比2.17%
Virtus LifeSci Biotech Products ETF
占比1.83%
Direxion Daily S&P Biotech Bull 3X Shares
占比1.47%
Invesco Nasdaq Biotechnology ETF
占比1.39%
ProShares Ultra Nasdaq Biotechnology
占比1.38%
iShares Biotechnology ETF
占比1.25%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据